There is one clinical trial.
The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to
COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or
hemoperfusion extracorporeal circuits under the FDA Emergency Use Authorization for this
CytoSorb device use. The intent of the registry is to gain understanding on how CytoSorb
hemoadsorption provides clinical benefit to COVID-19 ICU patients.
Primary Outcomes
Measure: ICU mortality Time: From the date of start of CytoSorb use until the date of ICU discharge or date of death, whichever comes first, assessed up to 1 year
Secondary Outcomes
Measure: Duration of ECMO after start of CytoSorb Time: From the date of start of CytoSorb use until the date of cessation of ECMO or date of death, which ever comes first, assessed up to 1 year
Measure: Duration of mechanical ventilatory support after start of CytoSorb Time: From the date of start of CytoSorb use until the date of cessation of mechanical ventilatory support or date of death, which ever comes first, assessed up to 1 year
Measure: Duration of pharmacologic hemodynamic support after start of CytoSorb Time: From the date of start of CytoSorb use until the date of cessation of pharmacologic hemodynamic support or date of death, which ever comes first, assessed up to 1 year
Measure: Change in serum concentrations of inflammatory biomarkers after start of CytoSorb Time: From the day before start of CytoSorb use until the day after cessation of CytoSorb use